$SAVA

cassavasciences.com/news-releases/…

Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials

$SAVA

Cassava Sciences Announces Virtual Presentation at the AD/PD™ 2024 International Conference

cassavasciences.com/news-releases/…

$SAVA

cassavasciences.com/node/16806/pdf

Cassava Sciences Reports Full-year 2023 Financial Results and Corporate Updates

-$121.1 Million In Cash and Cash Equivalents at December 31, 2023, With an Additional $21.8 Million Raised In 2024 From Exercise of Warrants.

-A Total of Over 555…

$SAVA
#ENDALZ

cassavasciences.com/node/16791/pdf

Cassava Sciences Completes Dividend Distribution of Warrants to Shareholders

$SAVA

-Shareholders of Record Received Warrants to Purchase Shares of Common Stock.

-Warrants Trade on Nasdaq Under the Ticker “SAVAW”.

-Warrant Holders Who Choose to Exercise During an Early Period…

$SAVA

cassavasciences.com/news-releases/…

$SAVA

Cassava Sciences Reports Third Quarter 2023 Financial and Operating Results

-Enrollment completed for Phase 3 trials evaluating oral simufilam in Alzheimer's.

-Over 1,900 patients randomized in on-going Phase 3 trials.

-Top-line results for 52-week Phase 3 trial…

Cassava Sciences Completes Enrollment for Pivotal Phase 3 Program of Simufilam in Alzheimer’s Disease

$SAVA
#ENDALZ

1,929 patients randomized in a pair of Phase 3 trials to evaluate oral simufilam in Alzheimer's disease dementia.

Top-line results for on-going, 52-week Phase 3…

$SAVA

cassavasciences.com/news-releases/…

$SAVA

CUNY’s report makes no findings of data manipulation.

The “egregious misconduct” cited in the report relates to internal record-keeping failures at CUNY.

CUNY’s report finds that internal record-keeping failures “ prevented us [CUNY] from making an objective…

$SAVA

Cassava Sciences to Present at the Jefferies Biotech CNS/Neuro Summit in NY.

CEO to Present on Wednesday, October 11th, at 10:30am ET

cassavasciences.com/news-releases/…

$SAVA

Cassava Sciences Completes Patient Enrollment for Pivotal Phase 3 Clinical Trial of Oral Simufilam in Alzheimer’s Disease

804 Alzheimer’s Patients Are Enrolled in a Pivotal Phase 3 Clinical Trial.

A Second Pivotal Phase 3 Clinical Trial Is Expected to Complete…

$SAVA

Cassava Sciences Announces Science Publication That Confirms Mechanism of Action of Simufilam, a Novel Drug Candidate for People with Alzheimer’s Disease

cassavasciences.com/node/16526/pdf

$SAVA

Cassava Sciences Invited to Present in Four Upcoming Investor Conferences

cassavasciences.com/node/16496/pdf

$SAVA Cassava Sciences Reports Q2 2023 Financial Results and Operating Updates

cassavasciences.com/node/16466/pdf

$SAVA

Oral Simufilam Slowed Cognitive Decline in a Randomized Withdrawal Trial of Mild-to-Moderate Alzheimer’s Disease.
#ENDALZ

cassavasciences.com/node/16451/pdf